The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Respiratory tract infection incl. pneumonia
This complication was not found in every study (PMID 24485129)
Publications
Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial.
Respiratory research. 2018;19(1):196
Janson C, Johansson G, Ställberg B, Lisspers K, Olsson P, Keininger DL, Uhde M, Gutzwiller FS, Jörgensen L, Larsson K
Identifying the associated risks of pneumonia in COPD patients: ARCTIC an observational study.
Respiratory research. 2018;19(1):172
Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, Singh D, Tabberer M, Wise RA, Pascoe SJ, IMPACT Investigators
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.
The New England journal of medicine. 2018;378(18):1671-1680
Cascini S, Kirchmayer U, Belleudi V, Bauleo L, Pistelli R, Di Martino M, Formoso G, Davoli M, Agabiti N
Inhaled Corticosteroid Use in Chronic Obstructive Pulmonary Disease and Risk of Pneumonia: A Nested Case-Control Population-based Study in Lazio (Italy)-The OUTPUL Study.
COPD. 2017;14(3):311-317
The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients' life quality with COPD in Taiwan (IMPACT) study.
International journal of chronic obstructive pulmonary disease. 2016;11:2775-2783
Discontinuation of Inhaled Corticosteroids in COPD and the Risk Reduction of Pneumonia.
Chest. 2015;148(5):1177-1183
Inhaled corticosteroids in COPD: the clinical evidence.
The European respiratory journal. 2015;45(2):525-37
Crim C, Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Lettis S, Calverley PM
Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD.
Annals of the American Thoracic Society. 2015;12(1):27-34
Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis.
International journal of chronic obstructive pulmonary disease. 2014;9:457-68
Meta-review: adverse effects of inhaled corticosteroids relevant to older patients.
Drugs. 2014;74(5):539-47
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease.
The Cochrane database of systematic reviews. 2014;2014(3):CD010115
Inhaled corticosteroids in COPD and the risk of serious pneumonia.
Thorax. 2013;68(11):1029-36
Inhaled corticosteroids and the risk of pneumonia in people with asthma: a case-control study.
Chest. 2013;144(6):1788-1794
Risks of pneumonia in patients with asthma taking inhaled corticosteroids.
American journal of respiratory and critical care medicine. 2011;183(5):589-95
Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia.
American journal of respiratory and critical care medicine. 2007;176(2):162-6